Valeant Pharmaceuticals Announces 2013 Annual Meeting Results

LAVAL, Quebec, May 21, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of ten directors nominated at its 2013 annual meeting of shareholders today.  The detailed results of the vote for the election of directors are set out below: 

Name


For


Withheld








Ronald H. Farmer


235,731,934


1,964,748


Robert A. Ingram


233,865,876


3,830,806


Theo Melas-Kyriazi


237,081,508


615,174


G. Mason Morfit


235,623,283


2,073,399


J. Michael Pearson


232,521,825


5,174,857


Robert N. Power


235,168,850


2,527,832


Norma A. Provencio


237,125,741


570,941


Howard B. Schiller


221,521,559


16,175,123


Lloyd M. Segal


236,082,529


1,614,153


Katharine Stevenson


234,501,146


3,195,536


At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement; appointed PricewaterhouseCoopers LLP (United States) as the Company's independent registered public accounting firm until the close of the Company's 2014 annual meeting of shareholders; and approved the continuance of the Company from the Canada Business Corporations Act to the British Columbia Business Corporations Act.

The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site, www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

SOURCE Valeant Pharmaceuticals International, Inc.



RELATED LINKS
http://www.valeant.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.